Helicobacter pylori: Multiple resistance in patients from Bogotá, Colombia
Abstract
Introduction: The main cause for Helicobacter pylori infection treatment failure is antibiotic resistance, where clarithromycin and metronidazole play the main role. In Colombia, primary resistance as a consequence of the use of these two antibiotics and excessive levofloxacin use is above the accepted limit (13.6%, 83%, and 16%, respectively). Despite this fact, empirical therapies that include the combination of these antibiotics are used in patients with previous therapeutic failure.
Objective: To determine antibiotic resistance in patients previously treated for H. pylori in Bogotá, Colombia.
Materials and methods: We conducted a descriptive study that included ten isolates obtained from five patients with three or four previous failed treatments for H. pylori.
Antibiotic resistance to amoxicillin, clarithromycin, levofloxacin, and metronidazole was investigated by agar dilution and confirmed by DNA sequencing (Magrogen, Korea).
Results: Eight isolates were resistant to two or more antibiotics. All isolates were resistant to levofloxacin. Susceptibility patterns in isolates from the gastric antrum and the body of the stomach were different in three patients.
Conclusion: As far as we know, this is the first evidence of multiple H. pylori resistance in Colombia in previously treated patients. Results demonstrated the consequences of using an ineffective antibiotic scheme and the need to assess antibiotic susceptibility in different anatomical sites of the stomach. The consequences of multiple resistance decrease possible antibiotic effectiveness to eradicate H. pylori in the future.
Downloads
References
Otero W, Gómez M, Castro D. Gastric carcinogenesis. Revista Colombiana de Gastroenterología. 2009;24:314-29.
IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon: International Agency for Research in Cancer; 2014. p. 1-59.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1-15. https://doi.org/10.1136/gutjnl-2015-309252
Malfertheiner P, Megraud F, Morain CAO, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. https://doi.org/10.1136/gutjnl-2016-312288
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Gastroenterol. 2018;155:1372-82. https://doi.org/10.1053/j.gastro.2018.07.007
Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21:13432-7. https://doi.org/10.3748/wjg.v21.i48.13432
Organización Mundial de la Salud. La OMS publica la lista de las bacterias para las que se necesitan urgentemente nuevos antibióticos. Fecha de consulta: 13 de octubre de 2018. Disponible en: http://www.who.int/es/news-room/detail/27-02-2017-who-publishes-list-ofbacteria-for-which-new-antibiotics-are-urgently-needed
Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and antibiotic resistance, a continuing and intractable problem. Helicobacter. 2016;21:349-63. https://doi.org/10.1111/hel.12299
Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother. 2009;63:648-53. https://doi.org/10.1093/jac/dkp003
Otth L, Wilson M, Fernández H, Otth C, Toledo C, Cárcamo V, et al. Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in southern Chile. Braz J Microbiol. 2011;42:442-7. https://doi.org/10.1590/S1517-83822011000200005
De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, et al. Primary clarithromycin resistance in Helicobacter pylori: The multicentric Italian clarithromycin resistance observational (MICRO) study. J Gastrointestin Liver Dis. 2011;20:235-9.
Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CM, Kusters JG. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2229-33. https://doi.org/10.1128%2FAAC.46.7.2229-2233.2002
Rimbara E, Noguchi N, Kawai T, Sasatsu M. Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. J Antimicrob Chemother. 2008;61:995-8. https://doi.org/10.1093/jac/dkn051
Trespalacios AA, Otero W, Caminos JE, Mercado MM, Ávila J, Rosero LE, et al. Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia. J Microbiol. 2013;51:448-52. https://doi.org/10.1007/s12275-013-2465-6
Kwon DH, Peña JA, Osato MS, Fox JG, Graham DY, Versalovic J. Frameshift mutations in rdxA and metronidazole resistance in North American Helicobacter pylori isolates. J Antimicrob Chemother. 2000;46:793-6.
Gerrits MM, Zoete MR De, Arents NL, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2996-3000. https://doi.org/10.1128/AAC.46.9.2996–3000.2002
Zhang Z, Liu Z, Zheng P, Tang F, Yang P. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastrointerol. 2010;16:1279-84. https://doi.org/10.3748/wjg.v16.i10.1279
Kutschke A, de Jonge BLM. Compound efflux in Helicobacter pylori compound efflux in Helicobacter pylori. Antimicrob Agents Chemother. 2005;49:3009-11. https://doi.org/10.1128/AAC.49.7.3009-3010.2005
Falsafi T, Ehsani A, Attaran B, Niknam V. Association of hp1181 and hp1184 genes with the active efflux phenotype in multidrug-resistant isolates of Helicobacter pylori. Jundishapur J Microbiol. 2016;20:e30726. https://doi.org/10.5812/jjm.30726
Liu Z, Zheng P, Yang P. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J Gastroenterol. 2008;14:5217-22. https://doi.org/10.3748/wjg.14.5217
Trespalacios AA, Otero Regino W, Mercado Reyes M. Helicobacter pylori resistance to metronidazole, clarithromycin and amoxicillin in Colombian patients. Revista Colombiana de Gastroenterología. 2010;25:31-8.
Trespalacios AA, Otero W, Arévalo GA, Poutou RA, Rimbara E, Graham DY. Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogotá-Colombia (2009-2014). PLoS ONE. 2016;11:1-10. https://doi.org/10.1371/journal.pone.0160007
Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis. 2000;19:538-41.
Boltin D, Ben-Zvi H, Perets TT, Kamenetsky Z, Samra Z, Dickman R, et al. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: Has the tide turned? J Clin Microbiol. 2015;53:522-7. https://doi.org/10.1128/JCM.03001-14
Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: A tutorial. Dig Liver Dis. 2008;40:650-8. https://doi.org/10.1016/j.dld.2008.02.030
Patel JB, Cockerill III FR, Alder J, Bradford PA, Eliopoulos GM, Hardy DJ, et al. Performance standards for antimicrobial susceptibility testing; Twenty-Fourth Informational Supplement. Wayne: CLSI; 2014. p. 1-230.
Wikler MA, Bush K, Cockerill III FR, Dudley MN, Eliopoulos GM, Hardy DJ, et al. Performance standards for antimicrobial susceptibility testing; Eighteenth Informational Supplement. Wayne: CLSI; 2008. p. 1-188.
Mégraud F. Antibiotic resistance in Helicobacter pylori infection. Br J Bull. 1998;54:207-16.
Mégraud F, Bénéjat L, Nina E, Ngoyi O, Lehours P. Molecular approaches to identify Helicobacter pylori antimicrobial resistance. Gastroenterol Clin North Am. 2015;44:577-96. https://doi.org/10.1016/j.gtc.2015.05.002
Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20:280-322. https://doi.org/10.1128/CMR.00033-06
Glocker E, Stueger H, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother. 2007;51:346-9. https://doi.org/10.1128/AAC.00614-06
Kim KS, Kang JO, Eun CS, Han DS, Choi TY. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J Korean Med Sci. 2002;17:599-603. https://doi.org/10.3346/jkms.2002.17.5.599
Tankovic J, Lascols C, Sculo Q, Petit J. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003;47:3942-4. https://doi.org/10.1128/AAC.47.12.3942-3944.2003
Ogata SK, Godoy APO, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645-8. https://doi.org/10.1097/MPG.0b013e31828b3669
Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:541-8. https://doi.org/10.4161/gmic.25930
Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58:930-5. https://doi.org/10.1099/jmm.0.009993-0
Karczewska E, Wojtas-bonior I, Sito E, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep. 2011;63:799-807.
Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109:1595-602. https://doi.org/10.1038/ajg.2014.222
Selgrad M, Tammer I, Langner C, Bornschein J, Meißle J, Kandulski A, et al. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol. 2014;20:16245-51. https://doi.org/10.3748/wjg.v20.i43.16245
Yakoob J, Fan X, Hu G, Yang H, Liu L, Liu S, et al. Polycolonization of Helicobacter pylori among Chinese subjects. Clin Microbiol Infect. 2001;7:187-92. https://doi.org/10.1046/j.1198-743x.2001.00226.x
Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter. 2003;8:202-6. https://doi.org/10.1046/j.1523-5378.2003.00145.x
Otero W, Gómez M, Otero L,Trespalacios A. Helicobacter pylori: ¿cómo se trata en el 2018? Rev Gastroenterol Peru. 2018;38:54-63.
Otero W, Trespalacios AA, Otero L, Vallejo M, Torres M, Pardo R, et al. Guía práctica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Revista Colombiaba de Gastroenterología. 2015;30(Suppl.1):17-33.
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177-86. https://doi.org/10.1016/j.cgh.2013.05.028
Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. World J Gastroenterol. 2015;21:10669-74. https://doi.org/10.3748/wjg.v21.i37.10669
Boyanova L, Evstatiev I, Gergova G, Yaneva P, Mitov I. Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance. Int J Antimicrob Agents. 2015;46:703-6. https://doi.org/10.1016/j.ijantimicag.2015.08.010
Shi J, Jiang Y, Zhao Y. Promising in vitro and in vivo inhibition of multidrug-resistant Helicobacter pylori by linezolid and novel oxazolidinone analogues. J Glob Antimicrob Resist. 2016;7:106-9. https://doi.org/10.1016/j.jgar.2016.07.016
Some similar items:
- Mónica Alejandra Bernal-Vargas, Jorge Alberto Cortés, Ricardo Sánchez, Cross-cultural adaptation of the community-acquired pneumonia score questionnaire in patients with mild-to-moderate pneumonia in Colombia , Biomedica: Vol. 37 No. 1 (2017)
- Claudia Patricia Acosta, Fabián Andrés Hurtado, Alba Alicia Trespalacios, Determination of single nucleotide mutations in the 23S rRNA gene of Helicobacter pylori related to clarithromycin resistance in a population from Cauca, Colombia , Biomedica: Vol. 34 (2014): Abril, Suplemento 1, Resistencia bacteriana
- Amanda Maestre, Jaime Carmona-Fonseca, Amanda Maestre, Alta frecuencia de mutaciones puntuales en pfcrt de Plasmodium falciparum y emergencia de nuevos haplotipos mutantes en Colombia , Biomedica: Vol. 28 No. 4 (2008)
- John Alexander Galindo, Fabio Aníbal Cristiano, Angélica Knudson, Rubén Santiago Nicholls, Ángela Patricia Guerra, Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum from three endemic malaria regions in Colombia , Biomedica: Vol. 30 No. 1 (2010)
- María Teresa Arango, Carlos Jaramillo, María Camila Montealegre, Mabel Helena Bohórquez, María del Pilar Delgado, Genetic characterization of the interleukin 1 β polymorphisms -511, -31 y +3954 in a Colombian population with dyspepsia , Biomedica: Vol. 30 No. 2 (2010)
- Andrés Javier Quiroga, Antonio Huertas, Alba Lucía Cómbita, María Mercedes Bravo, Variation in the number of EPIYA-C repeats in CagA protein from Colombian Helicobacter pylori strains and its ability to induce hummingbird phenotype in gastric epithelial cells , Biomedica: Vol. 30 No. 2 (2010)
- Lino E. Torres, Lidice González, Karelia Melián, Jordis Alonso, Arlenis Moreno, Mayrín Hernández, Orlando Reyes, Ludisleydis Bermúdez, Javier Campos, Guillermo Pérez-Pérez, Boris L. Rodríguez, EPIYA motif patterns among Cuban Helicobacter pylori CagA positive strains , Biomedica: Vol. 32 No. 1 (2012)
- Mercedes Figueroa, Armando Cortés, Álvaro Pazos, Luis Eduardo Bravo, Antimicrobial susceptibility of Helicobacter pylori with chronic gastritis , Biomedica: Vol. 32 No. 1 (2012)
- Yeison Harvey Carlosama , Claudia Patricia Acosta , Carlos Hernán Sierra , Carol Yovanna Rosero , Harold Jofre Bolaños, The Operative Link on Gastritis Assessment (OLGA) system as a marker for gastric cancer and dysplasia in a Colombian population at risk: A multicenter study , Biomedica: Vol. 43 No. Sp. 3 (2023): Enfermedades crónicas no transmisibles
- Diana Sanabria, Helena Groot, Julio Guzmán, María Claudia Lattig, An overview of oculocutaneous albinism: TYR gene mutations in five Colombian individuals , Biomedica: Vol. 32 No. 2 (2012)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
